These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 1341993)

  • 21. [Theoretical research for therapy of infection].
    Shimizu K
    Nihon Sanka Fujinka Gakkai Zasshi; 1991 Aug; 43(8):815-23. PubMed ID: 1655924
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prediction of antibiotic dosing intervals from in vitro susceptibility, pharmacokinetics and post-antibiotic effect: theoretical considerations.
    Turnidge JD
    Scand J Infect Dis Suppl; 1990; 74():137-41. PubMed ID: 2097701
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of the antibiotic dosage schedule on efficacy in experimental soft tissue infections.
    Gerber AU
    Scand J Infect Dis Suppl; 1990; 74():147-54. PubMed ID: 2097702
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro activity of moxifloxacin against common clinical bacterial isolates in Taiwan.
    Sheng WH; Wang JT; Chen YC; Chang SC; Luh KT
    J Microbiol Immunol Infect; 2001 Sep; 34(3):178-84. PubMed ID: 11605808
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Post-antibiotic and post-beta-lactamase inhibitor effects of ceftazidime plus sulbactam on extended-spectrum beta-lactamase-producing Gram-negative bacteria.
    Lavigne JP; Bonnet R; Michaux-Charachon S; Jourdan J; Caillon J; Sotto A
    J Antimicrob Chemother; 2004 Apr; 53(4):616-9. PubMed ID: 14985275
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A peptide derived from human bactericidal/permeability-increasing protein (BPI) exerts bactericidal activity against Gram-negative bacterial isolates obtained from clinical cases of bovine mastitis.
    Chockalingam A; McKinney CE; Rinaldi M; Zarlenga DS; Bannerman DD
    Vet Microbiol; 2007 Nov; 125(1-2):80-90. PubMed ID: 17560054
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro activity of the novel diaminopyrimidine, iclaprim, in combination with folate inhibitors and other antimicrobials with different mechanisms of action.
    Laue H; Weiss L; Bernardi A; Hawser S; Lociuro S; Islam K
    J Antimicrob Chemother; 2007 Dec; 60(6):1391-4. PubMed ID: 17962215
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The post-antibiotic effect of antimicrobial combinations in a neutropenic murine thigh infection model.
    Gudmundsson S; Einarsson S; Erlendsdottir H; Moffat J; Bayer W; Craig WA
    J Antimicrob Chemother; 1993 May; 31 Suppl D():177-91. PubMed ID: 8335520
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical and economic burden of antimicrobial resistance.
    Maragakis LL; Perencevich EN; Cosgrove SE
    Expert Rev Anti Infect Ther; 2008 Oct; 6(5):751-63. PubMed ID: 18847410
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Once-daily versus multiple-daily dosing of aminoglycosides.
    Craig WA
    J Chemother; 1995 Jun; 7 Suppl 2():47-52. PubMed ID: 8622110
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tigecycline: first of a new class of antimicrobial agents.
    Rose WE; Rybak MJ
    Pharmacotherapy; 2006 Aug; 26(8):1099-110. PubMed ID: 16863487
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibacterial activity of bioconverted eicosapentaenoic (EPA) and docosahexaenoic acid (DHA) against foodborne pathogenic bacteria.
    Shin SY; Bajpai VK; Kim HR; Kang SC
    Int J Food Microbiol; 2007 Jan; 113(2):233-6. PubMed ID: 16860896
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Conserving antibiotics for the future: new ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective.
    Mouton JW; Ambrose PG; Canton R; Drusano GL; Harbarth S; MacGowan A; Theuretzbacher U; Turnidge J
    Drug Resist Updat; 2011 Apr; 14(2):107-17. PubMed ID: 21440486
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Post-antibiotic effects in experimental infection models: relationship to in-vitro phenomena and to treatment of infections in man.
    Craig WA
    J Antimicrob Chemother; 1993 May; 31 Suppl D():149-58. PubMed ID: 8335516
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetic contributions to postantibiotic effects. Focus on aminoglycosides.
    Zhanel GG; Craig WA
    Clin Pharmacokinet; 1994 Nov; 27(5):377-92. PubMed ID: 7851055
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Postantibiotic effect of imipenem on gram-positive and gram-negative micro-organisms.
    Baquero F; Culebras E; Patrón C; Pérez-Díaz JC; Medrano JC; Vicente MF
    J Antimicrob Chemother; 1986 Dec; 18 Suppl E():47-59. PubMed ID: 3546247
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibacterial activity of lactophoricin, a synthetic 23-residues peptide derived from the sequence of bovine milk component-3 of proteose peptone.
    Campagna S; Mathot AG; Fleury Y; Girardet JM; Gaillard JL
    J Dairy Sci; 2004 Jun; 87(6):1621-6. PubMed ID: 15453475
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Postantibiotic effect of aminoglycosides on gram-negative bacteria evaluated by a new method.
    Isaksson B; Nilsson L; Maller R; Sörén L
    J Antimicrob Chemother; 1988 Jul; 22(1):23-33. PubMed ID: 3139614
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vivo postantibiotic effect in a thigh infection in neutropenic mice.
    Vogelman B; Gudmundsson S; Turnidge J; Leggett J; Craig WA
    J Infect Dis; 1988 Feb; 157(2):287-98. PubMed ID: 3121761
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Postantibiotic effect of DX-619 against 16 gram-positive organisms.
    Pankuch GA; Appelbaum PC
    Antimicrob Agents Chemother; 2005 Sep; 49(9):3963-5. PubMed ID: 16127083
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.